. Overexpressing SMN in cortical neurons derived from iPSCs does not prevent trophic-factor-induced cell death. Related to Figure 3 . Healthy control -1016A (A) and BJ (B)-and types III (C), II (D) and I (E) SMA iPSCs were differentiated into cortical neurons by forcing the expression of neurogenin-2 (Zhang et al., 2013) . Subsequently, cells were transduced or SMNoverexpressing doxycycline-inducible lentivirus or RFP control. Six days later trophic factors (TF) were removed for nine days followed by fixation and staining of the cultures with anti-Brn2 and SMN antibodies. The quantifications of the SMN levels in the Brn2 + cortical neurons for each cell line are calculated by relating all groups to neurons transduced with the RFP-OE virus in presence of TF ("+TF RFP-OE") (One-way ANOVA test followed by Dunnet´s analysis; *p<0.05, **p<0.01, ***p<0.001, n=3). Quantification of fold intensity change of SMN protein levels normalized to Tubulin protein levels (Student's t-test; ***p<0.001, n=4). (C) SMN mRNA abundance was assessed by quantitative reverse transcription PCR in MN cultures treated with 0.3µM MLN4924 or DMSO for 3 days. SMN expression is indicated as the fold change of 2 -ΔΔCt with reference to GAPDH, normalized to the level in the DMSO control (n=5). (D) Quantification of SMA A2 MNs reveals that the number of high SMN expressors expressed relative to DMSO control increases with MLN4924 treatment (*p < 0.05, **p < 0.01, One-way ANOVA followed by Dunnett's multiple comparison test, n = 11). (E) Quantification of number high SMN Islet1 + MNs derived from SMA type I iPSCs after MLN4924 treatment (*p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA followed by Dunnett's multiple comparison test, n = 11). (F-G) Quantification of SMN levels in human MNs differentiated from type II and III SMA patient iPSCs. Cells were treated for 3 days with DMSO or increasing concentrations of MLN4924, fixed and subjected to immunocytochemistry for SMN and Islet1 to label the MNs. Concentration-dependent data were fitted to a non-linear regression equation using Prism (*p < 0.05, **p < 0.01, ***p < 0.001, Two-way ANOVA followed by Dunnett's multiple comparison test, n = 4). (H) Cell lysates from SMA type II iPSC-derived MNs treated with DMSO or increasing concentrations of MLN4924 for 3 days (***p < 0.001, One-way ANOVA followed by Dunnett's multiple comparison test, n = 3). (I-J) Lysates from SMA type II iPSC-derived MNs cultures treated with DMSO, MLN4924, C3 or the combination of both compounds for 3 days and immunoblotted for SMN and actin (*p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA followed by Dunnett's multiple comparison test, n = 4). (K-L) Quantification Islet1 + cells in human MN cultures differentiated from iPSCs derived from SMA type II and III patients. Cells were treated with DMSO or increasing concentrations of MLN4924 for 3 days, fixed, and subjected to immunocytochemistry. Concentration-dependent data were fitted to a non-linear regression equation using Prism. (*p<0.05**p < 0.01, One-way ANOVA followed by Dunnett's multiple comparison test, n=4). Representative images from the type II (L) and III (N) MN cultures treated with 1.25 µM DMSO or MLN4924 are shown. Scale bar = 50µm (*p<0.05, ** p < 0.01, ***p < 0.001, ANOVA followed by Dunnett's multiple comparison test, n=4). or DMSO. The three mutant mice are indicated with an asterisk and the other three are Wt or heterozygotes mice. Note that the mouse that received MLN4924 shows a notably healthier phenotype than the other two DMSO-treated mutants, and a similar size to the unaffected littermates. (H) Weight measurement of SMN∆7 mice and Wt littermates treated from PND 2 to 10 with MLN4924 or DMSO reveals a significant and prolonged increase in body weight with MLN4924 (*p < 0.05, **p < 0.01, ***p < 0.001, Two-way ANOVA followed by Dunnett's multiple comparison test, n = 5). (I) Kaplan-Meier plot to estimate the survival MLN4924 versus DMSO-treated SMN∆7 mice (**p < 0.01, Mantel-Cox and Gehan-Breslow-Wilcoxon tests were used to determine statistical significance; n = 5 mice per each group). Table S1 . Summary of the human SMA iPSCs lines used in the study. Table S2 . Summary of the human ALS iPSCs lines used in the study.Related to Figure 1 and 5.
Supplemental Experimental Procedures
Mouse Treatments. FVB mice were obtained from Charles River Laboratories. The original breeding pair of heterozygous SMNΔ7 mice (mSmn+/-;SMN2+/+;SMNΔ7+/+), on a FVB background and the Hb9-GFP mice, on a C57Bl/6/ background, were provided by the Jackson Laboratory. Heterozygous SMNΔ7 mice and Hb9-GFP mice were back-crossed to a FVB background for more than 10 generations. In theSMN∆7 SMA mouse model, which survives for ten-twelve days after birth, Smn has been deleted, and two copies of the human SMN2 transgene and two copies of the human SMN2 transgene lacking exon 7 have been inserted into the genome (Smn-/-;SMN2+/+;SMN∆7+/+;hb9::GFP). Kaplan-Meier analysis was performed to determine survival curves.
Spinal MN histology. Cervical regions were sectioned at 10µm thickness using a cryostat (Leica CM 1950) and collected on slides. Samples were rinsed in PBS, permeabilized in 2% Triton-X100 under constant shaking for 30 min and blocked in 10% normal goat serum (NGS), 1% Triton-X100, 3% bovine serum albumin in PBS for 30 min. Samples were incubated with primary antibodies overnight at 4C, subsequently washed with several changes of PBS shaking for an hour and incubated with secondary antibodies at room temperature for an hour. Samples were washed and mounted with Vectashield with DAPI (Vectorlabs).
Chemicals, Antibodies, and Plasmids. MLN4924 (Active Biochem), SMN2 splicing modulator C3 (obtained from PTC-Roche Therapeutics), MG132 (Calbiochem), Trichostatin A (TSA, Sigma Aldrich), Ouabain (Biomol), Panobinostat (Selleck) and M344 (Tocris) were used as indicated. Antibodies for rat HA and mouse actin (Sigma Aldrich), rabbit beta-tubulin and rabbit Islet1 (Abcam), mouse SMN (BD Biosciences), rabbit Brna2 (Cell Signaling), rabbit ubiquitin (Santa Cruz), rabbit caspase-3 (Cell Signaling), and rabbit cullin5 (Abcam) were used as indicated. cDNAs encoding human HA-tagged full-length SMN (FL) protein or a truncated SMN protein carrying a deletion of exon 7 (∆7) were cloned into the pEF-DEST51 vector using the Gateway cloning system (Thermo Fisher Scientific). Lentiviral RNAi plasmids targeting SMN and a non-silencing control from Open Biosystems were described previously (Makhortova et al., 2011) . Plasmids encoding the dominant negative forms of human Cullin1 (Plasmid #41911), Cullin2 (Plasmid #41912), Cullin3 (Plasmid #41913), Cullin4a (Plasmid #41914), Cullin4b (Plasmid #41915) and Cullin5 (Plasmid #41916) in PHAGE vector and PHAGE empty vector (plasmid Plasmid #44012) were purchased from Addgene and used for lentiviral production. RFP and SMN were cloned into the DOX-inducible TRIPZ vector (Thermo Scientific).
Biochemical Assays. The HA-FL SMN or ∆7 constructs contain a bi-cistronic mCherry expression cassette that allowed us to only consider the experiments where mCherry expression suggested equal transfection efficiency. Cells were lysed in RIPA buffer (Thermo Fisher Scientific) with complete protease and phosphatase inhibitors (Thermo Fisher Scientific). To promote solubilization of ubiquitinated conjugates and to disrupt non-covalent interactions, lysates were incubated with 2% SDS prior to immunoprecipitation and then diluted to a final concentration of 0.1%SDS.
Reverse Transcription-PCR. Quantitative reverse transcription PCR was performed as previously described (Makhortova et al., 2011) . Gene expression was normalized to GAPDH.
Mouse MN Differentiation and Survival Assays. ES cells were differentiated into MNs using an embryoid body method with treatments of retinoic acid (Sigma Aldrich), and a hedgehog agonist (Curis, Inc.). After 7 days, MNs were dissociated and plated into poly-ornithine coated 96-well plates (PerkinElmer) at a density of 80,000 cells per well. For the experiments designed to assess the effect of SMN knockdown on MN survival, the non-silencing control virus and the SMN shRNA viruses were titrated by quantifying the number of MNs expressing the reporter protein GFP. In both cases, the amount of virus used was the one that yielded an infection of approximately 80% of the wild-type Hb9::mCherry MNs. Following compound addition, cells were imaged in the Operetta live-imaging microscope (PerkinElmer) each day for four days, and the number of infected MNs was quantified by using the Columbus software.
SMN Overexpression Assay.
For quantification of SMN protein levels, SMN was detected in RFP-NS infected cultures by immunofluorescence using an anti-mouse secondary antibody conjugated with Alexa647, and in SMN-OE infected cultures the secondary used was Alexa546-conjugated. Islet1 + MNs were in both cases detected with a secondary antibody anti-rabbit conjugated with an Alexa488 fluorophore.
Human MN Differentiation and Survival Assays. The wild-type BJ line was obtained from the Harvard iPSC Core Facility. Two other control wild-type lines, 1016A (originally derived in the lab of Douglas Melton (Pagliuca et al., 2014) ) and 18a (originally derived in the lab of Kevin Eggan (Boulting et al., 2011) ) were also used as additional controls (Table 2 ). The human TDP43-G298S, SOD1-G85S and C9orf72 ALS iPSC lines were obtained from Kevin Eggan and reviewed by the Harvard Committee on the Use of Human Subjects (the Harvard IRB) and determined to be not human subjects research. The TDP43-M337V ALS iPSC line was obtained from George Daley, is freely available and was described in (Bilican et al., 2012) . This information is summarized in Table  2 . The Pediatric Neuromuscular Clinical Research Network recruited SMA patients and collected the fibroblasts later obtained by the Rubin lab. The Harvard iPSC Core generated the iPSC lines from the SMA patient fibroblasts and the Harvard IRB reviewed and determined to be not human subjects research. 14 patient fibroblast samples were reprogrammed, of which 7 were from type III patients, 5 from type II patients, and 2 from type I patients. 154 putative iPS colonies were picked and expanded, and 44 of these were subjected to further characterization. Cytogenetic analysis was performed in G-banded metaphase cells from the all the cell lines and of the 44, 40 were karyotypically normal, a ratio consistent with what has been reported for control cells (Taapken et al., 2011) . Karyotypic analyses were performed in all 40 lines and no aneuploidy was detected in any line (Lynes et al., manuscript in preparation). All hiPSC lines expressed markers of undifferentiated and completely reprogrammed human pluripotent stem cells, such as OCT4, alkaline phosphatase and NANOG and had the potential to differentiate into the 3 embryonic lineages, endoderm, ectoderm, and mesoderm types of cells, as expected for fully reprogrammed iPS lines (Takahashi et al., 2007) . Multiple reprogramming strategies were used (retrovirus, lentivirus, episomal, RNA transfection, and Sendai virus) and the results from these studies comparing reprogramming methods have been published elsewhere (Schlaeger et al., 2015) . The Cytotune kit (Thermo Fisher Scientific) was used for Sendai virus reprogramming. Retrovirus reprogramming was performed as previously described (Park et al., 2008) . Because the field is moving towards utilizing the non-integrative Sendai virus method of reprogramming, we chose 2 Sendai virus lines for our studies: a type III SMA and SMA2-A. We also used a SMA type I line, retrovirally-reprogrammed. The pluripotent stem cells were grown with StemBeads FGFG2 (StemCultures) and on the day of differentiation colonies were dissociated into single cells using Accutase. Human iPSCs were cultured as embryoid bodies and were treated with 1 µM Dorsomorphin (Stemgent) and 1 µM SB 431542 (Stemgent) to induce neural differentiation and, additionally, with 1 µM retinoic acid (Sigma Aldrich) at day 5 and smoothened agonist 1.3 (EMD Millipore) at day 7. After 10 days of embryoid body formation, colonies were plated on poly-ornithine, fibronectin and laminin coated plates to differentiate neural progenitors to MNs. At day 12, DAPT (2.5 µM, R&D Systems) was added and, at day 20, 2 µM Cytosine Arabinoside (Ara-c, Sigma Aldrich) was added to eliminate progenitors and dividing cells. After 30 days of differentiation, the cultures were dissociated with papain solution (Worthington) and plated as single cells on astrocyte-coated 384-well plates (Greiner). The medium used was Neurobasal containing 2% B27 and 1% N2 (Thermo Fisher Scientific) supplemented with 20 ng/ml of BDNF, GDNF, and CNTF.
Human Cortical Neuron Differentiation and Survival Assays. pTet-O-Ngn2-puro plasmid was obtained from Addgene (Plasmid #52047) and packaged into lentivirus by cotransfection with psPAX2 and VSVG in HEK293T cells. Accutase-dissociated single-cell iPSCs were seeded in Matrigel-coated 96 well plates at density of 3,000 cells per well in mTeSR1 (STEMCELL Technologies) with 5 µM Rock inhibitor (Y-27632, EMD Millipore). One day later cells were infected with Ngn2 and rtTA lentiviruses in DMEM/F12 based medium containing: N2 Supplement, Non-Essential Amino Acids, Penicillin-Streptomycin, human BDNF (10 ng/ml, R&D Systems), human NT-3 (10 ng/ml, PeproTech), mouse laminin (0.2 µg/ml), and Doxycycline (0.2 µg/ml).
Immunocytochemistry and Image Analysis. MNs were identified either by GFP or Islet fluorescence in the nucleus and nuclei were identified using Hoechst. A size and morphology threshold was used to eliminate apoptotic nuclei from quantification. After cell-identification and SMN-specific antibody staining, a constant cytoplasmic region (circle) around the nucleus was defined and, by using a fully automated imager and associated software, the intensities in the SMN channel of all the pixels in that region of the cell were added up giving the "total intensity" in arbitrary units. That number was then divided by the number of pixels in that region, resulting in the "mean intensity" (of a pixel in the cell) in a way that is independent of the cell size. The mean intensity of SMN per cell was averaged across 25 random fields per well and 3-5 wells per condition, containing in total hundreds to thousands of MNs in each experiment. For each experiment, five wells with no primary antibody were used to determine background fluorescence intensity. For analysis of the number of high SMN expressors, the SMN intensity representing the 90th percentile in the DMSO control condition was calculated, and the number of MNs with SMN levels with higher than that threshold was counted per well. For analysis of high, medium, and low SMN MN expressors, arbitrary SMN thresholds based on the DMSO-treated cells were established to bin the MNs into those three categories: high -the 10% highest SMN expressors -, low -the 40% expressing the lowest SMN amount -and medium -the remaining 50%. The distribution of the total population of MNs according to their SMN protein levels was represented in histograms, where the intensity of SMN immunostaining expressed in arbitrary units (AU) is binned on the X-axis and the number of MNs falling into each of those bins is shown on the Y axis. Each histogram shown includes measurements made on hundreds to thousands of MNs from one representative experiment per assay. Error bars in the histograms represent the standard error of the mean from 3-8 replicates. The SMN intensities obtained from the MN cultures in vitro (both mouse and human) are lower than the ones obtained from the spinal cord cryosections, but this difference can be explained by the many disparities between the two preparations, such as immunostaining protocols (immunofluorescence on cryosections versus immunofluorescence on multi-well plates), image capture microscopes (Nikon Eclipse Ti microscope versus Operetta live-imaging microscope), sample holding material (glass slides for spinal cord versus plastic plates for in vitro MNs).
